InnoPharma, a sterile product development company, announced the first generic launch of Olanzapine for injection, 10mg/vial (the generic equivalent of Zyprexa injection), in Canada.

Olanzapine is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or bipolar I mania.

Navneet Puri, Ph.D., president and chief executive officer of InnoPharma, stated, “This announcement is a key milestone for InnoPharma, as it represents the first international launch of one of our products. As such, it demonstrates our ability to work successfully with regulatory agencies outside the United States, thereby extending our footprint and opening up additional revenue opportunities. We are pleased to work with our collaborator, Sandoz Canada, on the launch of this important generic drug.”

On July 16, 2014, Pfizer and InnoPharma announced that they have entered into an agreement under which  Pfizer will acquire InnoPharma. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter.